Press release
Parkinson's Disease Market Poised for Remarkable Growth by 2032, Predicts DelveInsight | Key Players Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicin
Parkinson's Disease Market
The Parkinson's disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson's disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Parkinson's disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Parkinson's disease market.
Request for a Free Sample Report @ https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Parkinson's disease Market Report are:
• According to DelveInsight, Parkinson's disease market is expected to grow at a decent CAGR by 2032.
• As per DelveInsight analysis, the Parkinson's disease market size in the 7MM was approximately USD 3.2 billion in 2022.
• Leading Parkinson's disease companies working in the market are Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others
• Key Parkinson's disease Therapies expected to launch in the market are Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, Buntanetap, IPX203, NE3107, CVN424, CNM-Au8, ITI-214 (lenrispodun), Prasinezumab (RO7046015/RG7935/PRX002), and others.
Parkinson's disease Overview
Parkinson's disease is a degenerative ailment caused by the loss of nerve cells in the substantia nigra, a region of the brain that governs movement. The cause of Parkinson's disease is unknown, however, it has long been hypothesized that exposure to environmental risk factors, together with a hereditary vulnerability, may be one explanation. The vast majority of instances are assumed to be sporadic, while up to 20% of persons with Parkinson's disease also have a first-degree relative with the disease.
Learn more about Parkinson's disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's disease Market
The Parkinson's disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson's disease market trends by analyzing the impact of current Parkinson's disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Parkinson's disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Parkinson's disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Parkinson's disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Parkinson's disease Epidemiology
The Parkinson's disease epidemiology section provides insights into the historical and current Parkinson's disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Parkinson's disease market report also provides the diagnosed patient pool, trends, and assumptions.
Parkinson's disease Epidemiology Segmentation
• Parkinson's Disease Diagnosed Prevalent Population
• Parkinson's Disease Gender-specific Diagnosed Prevalent Population
• Parkinson's Disease Age-specific Diagnosed Prevalent Population
• Parkinson's Disease Stage-specific Diagnosed Prevalent Population
Explore more about Parkinson's disease Epidemiology @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's disease Drugs Uptake
This section focuses on the uptake rate of the potential Parkinson's disease drugs recently launched in the Parkinson's disease market or expected to be launched in 2019-2032. The analysis covers the Parkinson's disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Parkinson's disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Parkinson's disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Parkinson's disease Pipeline Development Activities
The Parkinson's disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Parkinson's disease key players involved in developing targeted therapeutics.
• Tavapadon: Cerevel Therapeutics/Pfizer
• P2B001: Pharma Two B
• ABBV-951 (foscarbidopa/foslevodopa): AbbVie
• BIIB122/DNL151: Biogen/Denali Therapeutics
• Buntanetap: Annovis Bio
• IPX203: Amneal Pharmaceuticals
• NE3107: BioVie
• CVN424: Cerevance
• CNM-Au8: Clene Nanomedicine
• ITI-214 (lenrispodun): Intra-Cellular Therapies
• Prasinezumab (RO7046015/RG7935/PRX002): Hoffmann-La Roche/Prothena Corporation
Request for a sample report to understand more about the Parkinson's disease pipeline development activities @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's disease Therapeutics Assessment
Major key companies are working proactively in the Parkinson's disease Therapeutics market to develop novel therapies which will drive the Parkinson's disease treatment markets in the upcoming years are Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others.
Learn more about the emerging Parkinson's disease therapies & key companies @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's disease Report Key Insights
1. Parkinson's disease Patient Population
2. Parkinson's disease Market Size and Trends
3. Key Cross Competition in the Parkinson's disease Market
4. Parkinson's disease Market Dynamics (Key Drivers and Barriers)
5. Parkinson's disease Market Opportunities
6. Parkinson's disease Therapeutic Approaches
7. Parkinson's disease Pipeline Analysis
8. Parkinson's disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Parkinson's disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Parkinson's disease Competitive Intelligence Analysis
4. Parkinson's disease Market Overview at a Glance
5. Parkinson's disease Disease Background and Overview
6. Parkinson's disease Patient Journey
7. Parkinson's disease Epidemiology and Patient Population
8. Parkinson's disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson's disease Unmet Needs
10. Key Endpoints of Parkinson's disease Treatment
11. Parkinson's disease Marketed Products
12. Parkinson's disease Emerging Therapies
13. Parkinson's disease Seven Major Market Analysis
14. Attribute Analysis
15. Parkinson's disease Market Outlook (7 major markets)
16. Parkinson's disease Access and Reimbursement Overview
17. KOL Views on the Parkinson's disease Market
18. Parkinson's disease Market Drivers
19. Parkinson's disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Get the Detailed TOC of the Parkinson's disease Market report @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Bacterial Meningitis Market: https://www.delveinsight.com/report-store/bacterial-meningitis-market
• Anaphylaxis Market: https://www.delveinsight.com/blog/food-allergy-treatment-landscape
• Choroidal Neovascularization Market: https://www.delveinsight.com/sample-request/choroidal-neovascularization-market
• Scleroderma Market: https://www.delveinsight.com/report-store/localized-scleroderma-market
• Bladder Cancer Market: https://www.delveinsight.com/report-store/bladder-cancer-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
• Generalized Anxiety Disorder Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Ankylosing Spondylitis Market: https://www.delveinsight.com/infographics/ankylosing-spondylitis-as-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Chronic Insomnia Market: https://www.delveinsight.com/report-store/chronic-insomnia-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
• Helicobacter Pylori Infection Market: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market
Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Market Poised for Remarkable Growth by 2032, Predicts DelveInsight | Key Players Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicin here
News-ID: 3345284 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
